Register Now: Beyond EDC: Designing a Connected Data Strategy for Predictive Clinical Development
News|Videos|November 21, 2025

Measuring ROI and Effectiveness in Multi-Touch Digital Campaigns

Explore methods to evaluate recruitment performance across multiple platforms, including engagement tracking, conversion analysis, and data-driven optimization for emerging digital spaces.

In a recent video interview with Applied Clinical Trials, Christian Bullock, digital marketing director at Trialbee, discussed strategies for using nontraditional digital platforms to enhance patient recruitment. He outlined three key factors—audience relevance and intent, content fit and creative potential, and quality of engagement—as critical for determining platform suitability. Bullock explained how platforms such as TikTok, Reddit, and Spotify attract distinct demographics and require tailored messaging, creative formats, and calls to action to support multi-touch recruitment funnels. He highlighted operational and compliance challenges on emerging or entertainment-focused platforms, noting the need for ongoing communication with ad policy teams and careful evaluation of platform restrictions. Bullock shared lessons learned from successful campaigns on Spotify, Nextdoor, and other emerging platforms, emphasizing the importance of testing, monitoring both engagement and conversion, and applying a data-driven approach to optimize ROI while maintaining compliance.

The below interview transcript was lightly edited for clarity.

ACT: As digital marketing expands into new spaces, how are you measuring ROI or effectiveness across platforms to ensure recruitment efforts remain cost-efficient and compliant?

Bullock: Yeah, we look at it from a funnel perspective. So a platform, and specifically measuring ROI or the effectiveness of that platform, there needs to be a goal or an intent around how that platform fits in an overall kind of marketing funnel.

So I think you should think about first and foremost, platforms need to coexist together. You can't just rely on one platform to do everything for you. That's not the case. So mentioning things like how an awareness campaign kind of plugs into maybe something around the consideration buying cycle, like a social media ad, which then can play into someone going to Google or another search engine, performing a search, finding the resource that you're advertising for, and filling out a form. So it's not necessarily looking at—we call it as marketers—a last-touch interaction point. It's a multi-touch journey where we're finding audiences touching ads in multiple ways, multiple times, until they're ready to start taking the next step of filling out a pre-screener form.

So it's looking at sea-level rises right around—are we seeing just a general uptick across the board when it comes to audiences completing that action we want them to do, which is going to be a pre-screen form filled, generally speaking, versus attributing that last touch to a specific platform?

Then I would also mention that it's important not just to look at that interaction or that pre-screen form fill, but look at engagement. So how are users engaging with your ads? Again, that could be a big-time indicator of whether your ad is speaking in the language that a patient or a care partner understands or not. If you're seeing high engagement rates but not that pull-through, start being curious and seeing—is this maybe something that is multi-touch, so users are maybe hitting a landing page website for the first or second time, but then they're coming back later on a third, fourth, or fifth and filling out a form.

So again, the ROI and looking at reporting and figuring out what's going on and what platforms are working well needs to be seen across the spectrum.

And thirdly, I would look at it as treating new spaces as just that—new, emerging spaces. To use an ice hockey analogy, you start off with a clean sheet of ice, so you can make some assumptions, you can have some hunches, but you're not going to really know what's going to work until you look at the data that comes back and [start] testing out different audiences and different collateral and seeing what's working.

After you do that, you start seeing and plugging into, okay, how does this work within kind of a multi-touch generation that we're seeing today when it comes to a user journey for advertisements? Are we seeing it, exploring it from an awareness standpoint—is it working really well there? Are we getting a lot of clicks, lots of engagement, or are we actually seeing a lot of conversion pull-through? So staying curious and looking at how that emerging platform is actually working based off the data that you can see based on your testing.


Related to this article

Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Where AI Governance in Clinical Development Falls Short
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, identifies three recurring failure modes in AI governance frameworks—and explains why responsible AI must be an ongoing operating discipline, not a one-time approval gate.
What Needs to Happen Beyond the Clinical Trial Modernization Act
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.